Joint Commission proposes requirements for new stroke certification

A new optional certification is being developed by the Joint Commission for hospitals which “have the capability of providing high-quality endovascular thrombectomy for patients with ischemic stroke.”

The program, known as the Thrombectomy-capable Stroke Center Advanced Certification, now has proposed requirements from the Joint Commission and they’re seeking input from the field before finalizing them.

Requirements are built off typical program management standards with additions specific to Thrombectomy-capable Stroke Center Certification, such as:

·         Having the capacity to perform mechanical thrombectomy for the treatment of ischemic stroke 24 hours a day, 7 days a week

·         Being able to perform Catheter angiography, Computed tomography (CT) of the head, Computed tomography angiography (CTA), MRI, and Magnetic resonance angiography (MRA) 24 hours a day, 7 days a week

·         Having a transfer agreement with at least one comprehensive stroke center

·         Protocols and care paths (preprinted or electronic documents) are available in the emergency department, acute care areas, and stroke unit for the acute assessment and treatment of patients with ischemic or hemorrhagic stroke

The full list of proposed requirements can be read here.

Comments on the certification standards will be accepted online or by mail through May 29. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.